Restenosis, the proliferation of smooth muscle cells (SMC) that line blood vessels, often follows angioplasty. Despite advances in cardiology, restenosis continues to affect up to 40% of the over 500,000 patients who undergo angioplasty each year. Applications of Antisense Therapies to Restenosis is the first volume to address the potential of using antisense therapies to inhibit the restenosis that occurs after percutaneous transluminal angioplasty and coronary stenting. The work critically examines the application of various antisense therapies for inhibiting restenosis.

Restenosis, the proliferation of smooth muscle cells (SMC) that line blood vessels, often follows angioplasty. Despite advances in cardiology, restenosis continues to affect up to 40% of the over 500,000 patients who undergo angioplasty each year. Applications of Antisense Therapies to Restenosis is the first volume to address the potential of using antisense therapies to inhibit the restenosis that occurs after percutaneous transluminal angioplasty and coronary stenting. The work critically examines the application of various antisense therapies for inhibiting restenosis.